Persistent Humoral Immunodeficiency with Rising Herpesvirus Loads Despite Successful IL-6 Blockade in a Patient with Idiopathic Multicentric Castleman Disease and IgM-λ Monoclonal Gammopathy

Technical Summary: Persistent Humoral Immunodeficiency with Rising Herpesvirus Loads Despite Successful IL-6 Blockade in iMCD

Problem Statement
Idiopathic multicentric Castleman disease (iMCD) is a rare, IL-6-driven hematological disorder typically characterized by systemic inflammation and polyclonal hypergammaglobulinemia. Standard therapeutic approaches target IL-6 signaling (e.g., via siltuximab) to resolve inflammation. However, this case presents a diagnostic and therapeutic paradox: a patient with iMCD who simultaneously exhibits profound hypogammaglobulinemia (severe IgG and IgA deficiency), an isolated IgM-λ monoclonal gammopathy, and multiple herpesvirus reactivations (EBV, CMV, HSV). The clinical challenge lies in the dissociation between the resolution of systemic inflammation and the persistence or worsening of humoral immunodeficiency and viral loads following IL-6 blockade.

Methodology
The study is a detailed case report of a 25-year-old male with a 20-year history of generalized lymphadenopathy and recurrent infections. The methodology involved:

• Diagnostic Workup: Comprehensive laboratory profiling including serum immunoglobulin quantification, immunofixation electrophoresis, free light chain analysis, and viral DNA load monitoring (EBV, CMV, HSV).
• Histopathological Analysis: Lymph node excisional biopsy and bone marrow aspiration/biopsy were performed. Immunohistochemistry (IHC) and flow cytometry were utilized to characterize lymphoid architecture and rule out malignancies such as Waldenström macroglobulinemia (testing for MYD88 L265P mutation) and HHV-8-associated MCD.
• Therapeutic Intervention: The patient underwent three cycles of siltuximab (11 mg/kg every 3 weeks).
• Longitudinal Monitoring: Clinical symptoms, inflammatory markers (CRP, ESR), immunoglobulin levels, monoclonal protein burden, and viral loads were tracked pre- and post-treatment.

Key Results

• Baseline Profile: The patient presented with severe hypogammaglobulinemia (IgG <0.33 g/L, IgA 0.07 g/L), elevated IgM-λ monoclonal protein (11.10 g/L), and confirmed reactivation of EBV, CMV, and HSV.
• Pathological Findings: Lymph node biopsy confirmed iMCD (HHV-8 negative) with follicular hyperplasia and expanded mantle zones. Bone marrow biopsy excluded Waldenström macroglobulinemia (no lymphoplasmacytic infiltration, MYD88 wild-type).
• Response to Siltuximab:
  • Inflammatory Resolution: Systemic inflammation improved significantly; CRP decreased from 21.8 to 15.4 mg/L, ESR normalized (64 to 8 mm/h), and lymphadenopathy regressed markedly.
  • Immunological Persistence: Hypogammaglobulinemia remained unchanged (IgG <0.33 g/L, IgA 0.07 g/L). The IgM-λ clone showed only a marginal reduction (11.10 to 9.62 g/L).
  • Viral Progression: Contrary to the resolution of inflammation, viral loads increased substantially: EBV-DNA rose from 189 to 431 copies/mL, CMV-DNA from 1066 to 3470 copies/mL, and HSV-DNA from 787 to 3093 copies/mL.

Key Contributions

• Identification of a Novel iMCD Endotype: The paper characterizes a previously unrecognized iMCD phenotype defined by the coexistence of IL-6-driven systemic inflammation and IL-6-independent severe humoral immunodeficiency with monoclonal B-cell proliferation.
• Therapeutic Uncoupling: The study demonstrates that the control of iMCD-associated inflammation via IL-6 blockade does not equate to immune reconstitution. Specifically, the humoral immunodeficiency and the IgM-λ clone are independent of the IL-6 signaling pathway.
• Paradoxical Viral Dynamics: The case provides clinical evidence that IL-6 blockade may unmask or exacerbate underlying viral replication in patients with pre-existing severe immunodeficiency, potentially due to the removal of residual IL-6-mediated antiviral signaling.

Significance and Claims
The authors claim this case reveals a distinct iMCD endotype that challenges the paradigm of polyclonal hypergammaglobulinemia in iMCD. The primary significance lies in the finding that successful anti-IL-6 therapy can resolve systemic inflammation while failing to correct, and potentially worsening, underlying immunodeficiency and viral loads.

Consequently, the paper asserts that for iMCD patients presenting with monoclonal gammopathy and severe hypogammaglobulinemia, inflammation remission is insufficient for clinical management. The authors propose a dual-strategy approach:

1. Immunological Support: Lifelong immunoglobulin replacement and antiviral prophylaxis are essential to manage the persistent immunodeficiency and rising viral loads.
2. Hematological Surveillance: Long-term monitoring is required to detect potential clonal evolution toward symptomatic Waldenström macroglobulinemia or EBV-associated lymphoproliferative disorders.

The study concludes that this case expands the clinical spectrum of iMCD and necessitates a multi-dimensional management strategy that addresses both the inflammatory and immunodeficient components of the disease independently.